Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s stock price hit a new 52-week high on Monday . The stock traded as high as $28.67 and last traded at $28.29, with a volume of 227271 shares trading hands. The stock had previously closed at $27.55.
Gemini Therapeutics Stock Down 1.6 %
The company’s fifty day moving average is $49.89 and its two-hundred day moving average is $54.22. The stock has a market cap of $1.21 billion, a price-to-earnings ratio of -28.29 and a beta of -0.12.
Gemini Therapeutics Company Profile
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Read More
- Five stocks we like better than Gemini Therapeutics
- Investing in the High PE Growth Stocks
- AMD is Down 35%. Now is the Time to Buy the Dip
- Consumer Discretionary Stocks Explained
- Amazon Stands Tall: New Highs Are in Sight
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Chesapeake Energy Stock is The Energy Play, Earnings Confirm
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
